Department of Community Medicine , Institute of Health and Society, University of Oslo , Oslo , Norway.
Department of General Practice , Institute of Health and Society, University of Oslo , Oslo , Norway.
BMJ Open Diabetes Res Care. 2014 Oct 13;2(1):e000026. doi: 10.1136/bmjdrc-2014-000026. eCollection 2014.
Despite the suggested role of vitamin D in the prevention of diabetes and cardiovascular disease or its risk factors, the evidence is not consistent and there is a paucity of randomized controlled trials in this field. We aimed to investigate the effect of 16-week daily vitamin D3 supplementation on glycated hemoglobin (HbA1c), fructosamine, body mass index (BMI), and serum lipids.
Double-blind, randomized, placebo-controlled trial.
Immigrant community centers in Oslo, Norway.
251 healthy adults aged 18-50 years with a non-Western immigrant background. All participants performed the baseline test and 215 (86%) returned to the follow-up test.
16 weeks of daily oral supplementation with either 10 μg vitamin D3, 25 μg vitamin D3, or placebo.
Difference in absolute change during the 16-week intervention between the intervention groups combined (10 or 25 μg of vitamin D3/day) and placebo, in HbA1c, fructosamine, serum lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and BMI.
A total of 215 (86%) participants completed the study. Serum 25-hydroxyvitamin D increased from 29 nmol/L at baseline to 49 nmol/L after intervention, with little change in the placebo group. However, there was no difference in change of HbA1c between those receiving vitamin D3 compared with placebo (mean difference: 0.01% (95% CI -0.04 to 0.06, p=0.7)). Neither did the vitamin D3 supplementation have any effect on the other end points: fructosamine, serum lipids, and BMI.
16-week vitamin D3 supplementation to healthy immigrants from South Asia, the Middle East, or Africa and now living in Norway with low vitamin D status did not improve HbA1c, fructosamine, lipid profiles, or BMI. An updated meta-analysis of similar published trials showed that our results were generally consistent with those of other studies.
NCT01263288.
尽管维生素 D 被认为可预防糖尿病和心血管疾病或其危险因素，但相关证据并不一致，且该领域缺乏随机对照试验。我们旨在研究 16 周每日维生素 D3 补充对糖化血红蛋白（HbA1c）、果糖胺、体重指数（BMI）和血清脂质的影响。
双盲、随机、安慰剂对照试验。
挪威奥斯陆的移民社区中心。
251 名年龄在 18-50 岁之间、具有非西方移民背景的健康成年人。所有参与者均进行了基线测试，其中 215 名（86%）返回进行随访测试。
16 周每日口服补充 10μg 维生素 D3、25μg 维生素 D3 或安慰剂。
干预组（每日补充 10 或 25μg 维生素 D3）与安慰剂组在 16 周干预期间 HbA1c、果糖胺、血清脂质（总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯）和 BMI 的绝对变化差异。
共有 215 名（86%）参与者完成了研究。血清 25-羟维生素 D 从基线时的 29nmol/L 增加到干预后的 49nmol/L，安慰剂组变化不大。然而，与安慰剂相比，接受维生素 D3 治疗的患者 HbA1c 变化无差异（平均差异：0.01%（95%CI-0.04 至 0.06，p=0.7））。维生素 D3 补充也没有对其他终点产生影响：果糖胺、血清脂质和 BMI。
16 周维生素 D3 补充对目前居住在挪威、维生素 D 状态较低的南亚、中东或非洲移民的健康成年人并未改善 HbA1c、果糖胺、血脂谱或 BMI。对类似已发表试验的更新荟萃分析表明，我们的结果与其他研究的结果基本一致。
NCT01263288。
